Rutgers Cancer Institute of New Jersey (CINJ)
Academic institution
New Brunswick
New Jersey, USA
Rutgers Cancer Institute together with RWJBarnabas Health is one of an elite group of comprehensive cancer centers in the U.S. designated by the National Cancer Institute and the only one in the state of New Jersey. This coveted designation gives Rutgers Cancer Institute the distinction of being among the best cancer research institutions in the nation. Rutgers Cancer Institute is also New Jersey’s leading cancer program as recognized by U.S. News and World Report’s Best Hospital rankings.
Rutgers Cancer Institute is committed to providing the most advanced, comprehensive, and compassionate cancer care to adults and children. Our dedication to excellence is fueled by the cutting-edge research led by our internationally recognized clinicians and researchers who, in partnership with RWJBarnabas Health, work tirelessly to move laboratory discoveries into clinical practice. Their discoveries in precision medicine, immunotherapy, cancer genomics, and other scientific areas are producing high-impact clinical trials that enable us to deliver the most sophisticated treatment plans to our patients today, and lay the groundwork for breakthrough cancer treatments of the future.
The National Cancer Institute’s Comprehensive Cancer Center designation is competitively awarded to an elite group of centers characterized by their scientific leadership, resources, and outstanding track record of research discoveries in basic, clinical, and population-based science. Designated centers must meet rigorous criteria in the areas of clinical care, research, prevention, and education, as well as demonstrate a substantial transdisciplinary approach that integrates each discipline-specific scientific area into one coordinated and comprehensive effort in the fight against cancer.
Rutgers Cancer Institute is also recognized by the NCI as a consortium cancer center in collaboration with Princeton University. This NCI-approved partnership brings together the research and scientific innovation of the top cancer researchers, scientists, and clinicians in the state of New Jersey.
Rutgers Cancer Institute conducts matrix-style investigations in basic, clinical, preventive, behavioral, and population-based research. In collaboration with Rutgers University and Princeton University as a consortium cancer center, we are leveraging the scientific discoveries of the state’s leading cancer researchers. We are keenly focused on fulfilling the cancer research needs of the most densely populated and industry-rich state in the nation.
Rutgers Cancer Institute research programs and core facilities enhance and support the cancer research of more than 230 members at Rutgers University and Princeton University, including the Princeton branch of Ludwig Cancer Research. Based at Princeton University, the Ludwig Princeton Branch is dedicated to the study of cancer metabolism. Combined with Ludwig’s leadership in cancer epigenetics and immunotherapy, advances in cancer metabolism generated at the Ludwig Princeton Branch will inform new strategies for cancer prevention and treatment. The clinical translation of Branch discoveries will be conducted in the tri-state area, including in partnership with RWJBarnabas Health and Rutgers Cancer Institute.
Our research programs includes: behavioral science, precision medicine, systems biology, oncogenesis, tumor virology and immunology, autophagy, and drug development and resistance. This is in addition to exploring cancer control and prevention, bioinformatics, cancer genomics, and the relationship between cellular and genetic alterations and tumor development.
Rutgers Cancer Institute is committed to providing the most advanced, comprehensive, and compassionate cancer care to adults and children. Our dedication to excellence is fueled by the cutting-edge research led by our internationally recognized clinicians and researchers who, in partnership with RWJBarnabas Health, work tirelessly to move laboratory discoveries into clinical practice. Their discoveries in precision medicine, immunotherapy, cancer genomics, and other scientific areas are producing high-impact clinical trials that enable us to deliver the most sophisticated treatment plans to our patients today, and lay the groundwork for breakthrough cancer treatments of the future.
The National Cancer Institute’s Comprehensive Cancer Center designation is competitively awarded to an elite group of centers characterized by their scientific leadership, resources, and outstanding track record of research discoveries in basic, clinical, and population-based science. Designated centers must meet rigorous criteria in the areas of clinical care, research, prevention, and education, as well as demonstrate a substantial transdisciplinary approach that integrates each discipline-specific scientific area into one coordinated and comprehensive effort in the fight against cancer.
Rutgers Cancer Institute is also recognized by the NCI as a consortium cancer center in collaboration with Princeton University. This NCI-approved partnership brings together the research and scientific innovation of the top cancer researchers, scientists, and clinicians in the state of New Jersey.
Rutgers Cancer Institute conducts matrix-style investigations in basic, clinical, preventive, behavioral, and population-based research. In collaboration with Rutgers University and Princeton University as a consortium cancer center, we are leveraging the scientific discoveries of the state’s leading cancer researchers. We are keenly focused on fulfilling the cancer research needs of the most densely populated and industry-rich state in the nation.
Rutgers Cancer Institute research programs and core facilities enhance and support the cancer research of more than 230 members at Rutgers University and Princeton University, including the Princeton branch of Ludwig Cancer Research. Based at Princeton University, the Ludwig Princeton Branch is dedicated to the study of cancer metabolism. Combined with Ludwig’s leadership in cancer epigenetics and immunotherapy, advances in cancer metabolism generated at the Ludwig Princeton Branch will inform new strategies for cancer prevention and treatment. The clinical translation of Branch discoveries will be conducted in the tri-state area, including in partnership with RWJBarnabas Health and Rutgers Cancer Institute.
Our research programs includes: behavioral science, precision medicine, systems biology, oncogenesis, tumor virology and immunology, autophagy, and drug development and resistance. This is in addition to exploring cancer control and prevention, bioinformatics, cancer genomics, and the relationship between cellular and genetic alterations and tumor development.
